Are Cancer Drugs Worth the Money? MSKCC Tool Tests Pricing Rationale

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A health services researcher at Memorial Sloan-Kettering Cancer Center has proposed a method for assessing whether cancer drugs are rationally priced.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login